Virpax Pharmaceuticals, Inc.
VRPX
$0.02
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.26M | 7.56M | 11.40M | 11.85M | 11.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.08M | 13.37M | 17.56M | 17.34M | 16.94M |
| Operating Income | -12.08M | -13.37M | -17.56M | -17.34M | -16.94M |
| Income Before Tax | -12.07M | -13.24M | -17.23M | -16.89M | -15.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.07 | -13.24 | -17.23 | -16.89 | -15.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.07M | -13.24M | -17.23M | -16.89M | -15.19M |
| EBIT | -12.08M | -13.37M | -17.56M | -17.34M | -16.94M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -137.61 | -229.33 | -351.20 | -374.93 | -337.19 |
| Normalized Basic EPS | -86.01 | -143.33 | -219.50 | -234.33 | -228.09 |
| EPS Diluted | -137.61 | -229.33 | -351.20 | -374.93 | -337.19 |
| Normalized Diluted EPS | -86.01 | -143.33 | -219.50 | -234.33 | -228.09 |
| Average Basic Shares Outstanding | 17.72M | 9.34M | 5.71M | 4.87M | 4.87M |
| Average Diluted Shares Outstanding | 17.72M | 9.34M | 5.71M | 4.87M | 4.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |